Nurix Therapeutics, Inc. (NRIX) Financial Statements
$25.34NASDAQ: NRIXMarket Cap $2.77B
Nurix Therapeutics, Inc. most recently reported annual revenue of $84.0M, a net loss of $264.0M. Revenue grew at an average annual rate of 36.1% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Nurix Therapeutics, Inc.: Revenue rose from $37.0M in 2018 to $84.0M in 2025, a change of +127.0% over 7 years; net profit was positive in 0 of 8 reported years; operating margin moved from -26.0% to -340.2%, a shift of -314.2 percentage points; the most recent year shows a net loss of $264.0M.
Income Statement — 8 Years (USD millions)
Metric
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$37.0M
$31.0M
$18.0M
$30.0M
$39.0M
$77.0M
$55.0M
$84.0M
Operating Expenses
$47.0M
$53.0M
$83.0M
$148.0M
$222.0M
$232.0M
$268.0M
$370.0M
Operating Profit
$-10.0M
$-22.0M
$-65.0M
$-118.0M
$-184.0M
$-155.0M
$-213.0M
$-286.0M
Operating Margin
-26.0%
-71.5%
-364.7%
-396.3%
-476.0%
-201.4%
-390.5%
-340.2%
Other Income
$1.0M
$1.0M
$1.0M
$1.0M
$4.0M
$11.0M
$20.0M
$22.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
Depreciation
$3.0M
$2.0M
$2.0M
$2.0M
$4.0M
$6.0M
$8.0M
$19.0M
Profit Before Tax
$-9.0M
$-21.0M
$-64.0M
$-117.0M
$-180.0M
$-144.0M
$-193.0M
$-264.0M
Tax
$-5.7M
$-1.1M
$32.2M
$-110,000
$0
$0
$-140,000
$-290,000
Net Profit
$-9.0M
$-22.0M
$-43.0M
$-117.0M
$-180.0M
$-144.0M
$-194.0M
$-264.0M
EPS
$-0.59
$-0.56
$-2.76
$-2.73
$-3.71
$-2.65
$-2.88
$-3.05
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$18.0M
$15.0M
$17.0M
$12.0M
$13.0M
$13.0M
$18.0M
$44.0M
$8.0M
$14.0M
$6.0M
$9.0M
Operating Expenses
$58.0M
$60.0M
$62.0M
$61.0M
$67.0M
$78.0M
$81.0M
$92.0M
$99.0M
$97.0M
$99.0M
$103.0M
Operating Profit
$-40.0M
$-45.0M
$-45.0M
$-49.0M
$-55.0M
$-65.0M
$-63.0M
$-48.0M
$-91.0M
$-83.0M
$-92.0M
$-94.0M
Operating Margin
-216.7%
-299.1%
-272.6%
-401.4%
-433.8%
-486.7%
-340.7%
-109.7%
-1157.7%
-612.0%
-1479.5%
-1041.7%
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
$-37.0M
$-42.0M
$-41.0M
$-44.0M
$-49.0M
$-59.0M
$-56.0M
$-43.0M
$-86.0M
$-78.0M
$-87.0M
$-90.0M
Tax
$0
$0
$-220,000
$-200,000
$-170,000
$-10,000
$0
$-1.8M
$0
$0
$0
$300,000
Net Profit
$-37.0M
$-42.0M
$-42.0M
$-45.0M
$-49.0M
$-59.0M
$-56.0M
$-43.0M
$-86.0M
$-78.0M
$-87.0M
$-90.0M
EPS
$-0.68
$-0.77
$-0.76
$-0.71
$-0.67
$-0.75
$-0.67
$-0.52
$-1.03
$-0.82
$-0.79
$-0.81
Over the 8 years reported for Nurix Therapeutics, Inc., cash stood at $247.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 7.06 times.
Balance Sheet — 8 Years (USD millions)
Metric
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$45.0M
$44.0M
$396.0M
$477.0M
$417.0M
$356.0M
$669.0M
$688.0M
Current Assets
$41.0M
$39.0M
$298.0M
$311.0M
$318.0M
$296.0M
$619.0M
$607.0M
Cash
$26.0M
$35.0M
$119.0M
$81.0M
$64.0M
$55.0M
$110.0M
$247.0M
Inventory
$0
$0
$0
$0
$-1.0M
$0
$0
$0
Receivables
$0
$0
$11.0M
$6.0M
$1.0M
$1.0M
$2.0M
$0
Fixed Assets
$4.0M
$4.0M
$7.0M
$25.0M
$30.0M
$48.0M
$46.0M
$73.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$14.0M
$3.0M
$253.0M
$353.0M
$309.0M
$241.0M
$500.0M
$346.0M
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$34.0M
$54.0M
$106.0M
$134.0M
$113.0M
$155.0M
$142.0M
$149.0M
Current Liabilities
$33.0M
$16.0M
$45.0M
$66.0M
$71.0M
$87.0M
$96.0M
$86.0M
Borrowings
$0
$0
$0
$13.0M
$12.0M
$31.0M
$28.0M
$56.0M
Other Liabilities
$34.0M
$54.0M
$106.0M
$121.0M
$101.0M
$124.0M
$114.0M
$94.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$-37.0M
$-58.0M
$290.0M
$342.0M
$304.0M
$200.0M
$527.0M
$539.0M
For Nurix Therapeutics, Inc., operating cash flow was positive in 1 of 8 reported years; free cash flow in the latest year was negative at $263.0M; free cash flow was positive in 0 of 8 years.
Cash Flow Statement — 8 Years (USD millions)
Metric
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
$-32.0M
$1.0M
$0
$-84.0M
$-160.0M
$-81.0M
$-173.0M
$-249.0M
Investing Cash Flow
$38.0M
$7.0M
$-259.0M
$-114.0M
$15.0M
$60.0M
$-267.0M
$134.0M
Financing Cash Flow
$0
$0
$1.0M
$4.0M
$98.0M
$0
$7.0M
$0
Net Cash Flow
$9.0M
$9.0M
$85.0M
$-39.0M
$-15.0M
$-10.0M
$55.0M
$137.0M
Free Cash Flow
$-33.0M
$-1.0M
$-5.0M
$-90.0M
$-172.0M
$-90.0M
$-182.0M
$-263.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.25
EV / EBITDA
-7.37
FCF Yield
-12.87%
Quick Ratio
6.34
Interest Coverage
—
Return 1Y
109.78%
Return 3Y
134.36%
Return 5Y
-23.18%
Nurix Therapeutics, Inc. (NRIX) financials — frequently asked questions
What is Nurix Therapeutics, Inc.'s annual revenue?
Nurix Therapeutics, Inc. (NRIX) reported annual revenue of $84.0M in its most recent fiscal year.
What is Nurix Therapeutics, Inc.'s net profit?
Nurix Therapeutics, Inc. (NRIX) reported a net loss of $264.0M in its most recent fiscal year.
What is NRIX EV/EBITDA?
Nurix Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -7.37. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.